Form 4: Lineage Cell Therapeutics Executive Acquires Stock Options
SEC Form 4 Filing
George A. Samuel III, General Counsel/Secretary of Lineage Cell Therapeutics, acquired 650,000 employee stock options on March 7, 2024.
Summary
- On March 7, 2024, George A. Samuel III, the General Counsel/Secretary of Lineage Cell Therapeutics, Inc., acquired 650,000 employee stock options.
- The options have an exercise price of $1.13.
- One quarter of the options will vest on March 7, 2025, with the remainder vesting in 36 monthly installments thereafter, contingent upon continuous employment.
- The options expire on March 7, 2034.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and is typical for publicly traded companies. It provides transparency into the equity-based compensation of key personnel.
Stakeholder Impact
- The acquisition of stock options by a key executive could be viewed positively by shareholders as it aligns the executive's interests with the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 03/07/2024 | Date of transaction: George A. Samuel III acquired 650,000 employee stock options. |
| 03/07/2025 | One quarter of the options vest. |
| 03/07/2034 | Expiration date of the options. |
| 03/08/2024 | Date of signature on the Form 4. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.